| Literature DB >> 24485523 |
Jose Luis Perez-Gracia1, Sara Labiano1, Maria E Rodriguez-Ruiz1, Miguel F Sanmamed1, Ignacio Melero2.
Abstract
Inhibitory receptors on immune system cells respond to membrane-bound and soluble ligands to abort or mitigate the intensity of immune responses by raising thresholds of activation, halting proliferation, favoring apoptosis or inhibiting/deviating effector function differentiation. Such evolutionarily selected inhibitory mechanisms are termed check-points and therefore check-point inhibitors empower any ongoing anti-cancer immune response that might have been too weak or exhausted. Monoclonal antibodies (mAb) interfering with CTLA-4-CD80/86, PD-1 - PD-L1, TIM-3-GAL9 and LAG3-MHC-II belong to this category of check-point inhibitors. The anti-CTLA-4 mAb ipilimumab has been approved for metastatic melanoma. Anti-PD-1 and anti-PD-L1 mAbs have shown extremely encouraging clinical activity. The potential of combination strategies with these agents has recently been highlighted by clinical observations on CTLA-4+PD-1 combined blockade in melanoma patients.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24485523 DOI： 10.1016/j.coi.2014.01.002
Source DB: PubMed Journal: Curr Opin Immunol ISSN： 0952-7915 Impact factor: 7.486